CRMD vs PRAX

For growth investors, CorMedix Inc.

(CRMD) is the stronger pick with 617. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). CorMedix Inc. (CRMD) offers the better valuation at 3. 9x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate CorMedix Inc. (CRMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CorMedix Inc.

(CRMD) delivered a total return of -6. 9%, compared to -20. 8% for Praxis Precision Medicines, Inc. (PRAX). Over 10 years, the gap is even starker: PRAX returned -20. 9% versus CRMD's -51. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.

(PRAX) is the lower-risk stock at 1. 40β versus CorMedix Inc. 's 1. 42β — meaning CRMD is approximately 2% more volatile than PRAX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 37% for CorMedix Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CorMedix Inc.

(CRMD) is pulling ahead at 617. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: CorMedix Inc. grew EPS 780. 0% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CorMedix Inc.

(CRMD) is the more profitable company, earning 52. 3% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 52. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRMD leads at 48. 2% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — CRMD leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CRMD: 76.

8% to $14. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Praxis Precision Medicines, Inc.

(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (PRAX: -20. 9%, CRMD: -51. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CRMD is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.